Correction: THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer

Xing Zhou^#^{1

2

3

4}, Jiashu Han^#⁵, Anning Zuo^#¹, Yuhao Ba^#¹, Shutong Liu^#¹, Hui Xu¹, Yuyuan Zhang¹, Siyuan Weng¹, Zhaokai Zhou⁶, Long Liu⁷, Peng Luo⁸, Quan Cheng⁹, Chuhan Zhang¹⁰, Yukang Chen¹, Dan Shan¹¹, Benyu Liu¹², Shuaixi Yang¹³, Xinwei Han^{14

15

16}, Jinhai Deng¹⁷, Zaoqu Liu^{18

19

20

21}

Affiliations

¹ Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
² Interventional Institute of Zhengzhou University, Zhengzhou, Henan, 450052, China.
³ Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, 450052, China.
⁴ Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
⁵ Department of General Surgery, Peking Union Medical College Hospital, Beijing, 100020, China.
⁶ Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
⁷ Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
⁸ Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
⁹ Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
¹⁰ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
¹¹ Clinical Science Institute, University Hospital Galway, Galway, Ireland.
¹² Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
¹³ Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
¹⁴ Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. fcchanxw@zzu.edu.cn.
¹⁵ Interventional Institute of Zhengzhou University, Zhengzhou, Henan, 450052, China. fcchanxw@zzu.edu.cn.
¹⁶ Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, 450052, China. fcchanxw@zzu.edu.cn.
¹⁷ Richard Dimbleby Department of Cancer Research, Comprehensive Cancer Centre, Kings College London, London, UK. jinhaideng_kcl@163.com.
¹⁸ Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. liuzaoqu@163.com.
¹⁹ Interventional Institute of Zhengzhou University, Zhengzhou, Henan, 450052, China. liuzaoqu@163.com.
²⁰ Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, 450052, China. liuzaoqu@163.com.
²¹ Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. liuzaoqu@163.com.

^# Contributed equally.

PMID: 40571948
PMCID: PMC12199521
DOI: 10.1186/s12943-025-02388-6

Published Erratum

Correction: THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer

Xing Zhou et al. Mol Cancer. 2025.

. 2025 Jun 26;24(1):184.

doi: 10.1186/s12943-025-02388-6.

Authors

Affiliations

¹ Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
² Interventional Institute of Zhengzhou University, Zhengzhou, Henan, 450052, China.
³ Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, 450052, China.
⁴ Department of Pediatric Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
⁵ Department of General Surgery, Peking Union Medical College Hospital, Beijing, 100020, China.
⁶ Department of Urology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
⁷ Department of Hepatobiliary Surgery, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, Shaanxi, 710061, China.
⁸ Department of Oncology, Zhujiang Hospital, Southern Medical University, Guangzhou, China.
⁹ Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China.
¹⁰ Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China.
¹¹ Clinical Science Institute, University Hospital Galway, Galway, Ireland.
¹² Tianjian Laboratory of Advanced Biomedical Sciences, Academy of Medical Sciences, Zhengzhou University, Zhengzhou, China.
¹³ Department of Colorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou University, Zhengzhou, China.
¹⁴ Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. fcchanxw@zzu.edu.cn.
¹⁵ Interventional Institute of Zhengzhou University, Zhengzhou, Henan, 450052, China. fcchanxw@zzu.edu.cn.
¹⁶ Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, 450052, China. fcchanxw@zzu.edu.cn.
¹⁷ Richard Dimbleby Department of Cancer Research, Comprehensive Cancer Centre, Kings College London, London, UK. jinhaideng_kcl@163.com.
¹⁸ Department of Interventional Radiology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, 450052, China. liuzaoqu@163.com.
¹⁹ Interventional Institute of Zhengzhou University, Zhengzhou, Henan, 450052, China. liuzaoqu@163.com.
²⁰ Interventional Treatment and Clinical Research Center of Henan Province, Zhengzhou, Henan, 450052, China. liuzaoqu@163.com.
²¹ Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, 100730, China. liuzaoqu@163.com.

^# Contributed equally.

PMID: 40571948
PMCID: PMC12199521
DOI: 10.1186/s12943-025-02388-6

No abstract available

PubMed Disclaimer

Figures

See this image and copyright information in PMC

Erratum for

THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer.
Zhou X, Han J, Zuo A, Ba Y, Liu S, Xu H, Zhang Y, Weng S, Zhou Z, Liu L, Luo P, Cheng Q, Zhang C, Chen Y, Shan D, Liu B, Yang S, Han X, Deng J, Liu Z. Zhou X, et al. Mol Cancer. 2024 Dec 28;23(1):282. doi: 10.1186/s12943-024-02180-y. Mol Cancer. 2024. PMID: 39732719 Free PMC article.

References

1. Zhou X, Han J, Zuo A, et al. THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer. Mol Cancer. 2024;23:282. 10.1186/s12943-024-02180-y. - PMC - PubMed

Publication types

Actions

LinkOut - more resources

Full Text Sources
- BioMed Central
- PubMed Central
Miscellaneous
- NCI CPTAC Assay Portal

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Correction: THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer

Affiliations

Correction: THBS2 + cancer-associated fibroblasts promote EMT leading to oxaliplatin resistance via COL8A1-mediated PI3K/AKT activation in colorectal cancer

Authors

Affiliations

Figures

Erratum for

References

Publication types

LinkOut - more resources

Full Text Sources

Miscellaneous